If upcoming results from a Phase III trial of a new birch allergy drug are positive, Allergy Therapeutics’ (AGY) share price could find renewed momentum. The shares lost steam last year after bosses said the results would be delayed, but with data now due in the first quarter of 2019, would-be investors with room for risk in their portfolio could take advantage of the depressed share price.
Strong recent trading
Upcoming phase three birch results
First human trial for peanut allergy vaccine
Meetings with US regulators
Equity fundraising dilution risk
High cash burn